These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 31761062)

  • 41. Amyloid imaging with (18)F-florbetaben in Alzheimer disease and other dementias.
    Villemagne VL; Ong K; Mulligan RS; Holl G; Pejoska S; Jones G; O'Keefe G; Ackerman U; Tochon-Danguy H; Chan JG; Reininger CB; Fels L; Putz B; Rohde B; Masters CL; Rowe CC
    J Nucl Med; 2011 Aug; 52(8):1210-7. PubMed ID: 21764791
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Molecular Imaging and Updated Diagnostic Criteria in Lewy Body Dementias.
    Bohnen NI; Müller MLTM; Frey KA
    Curr Neurol Neurosci Rep; 2017 Aug; 17(10):73. PubMed ID: 28808912
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Clinical features of Pittsburgh compound-B-negative dementia.
    Takeuchi J; Shimada H; Ataka S; Kawabe J; Mori H; Mizuno K; Wada Y; Shiomi S; Watanabe Y; Miki T
    Dement Geriatr Cogn Disord; 2012; 34(2):112-20. PubMed ID: 22947919
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Progression of logopenic aphasia to frontotemporal dementia in an amyloid β-negative and
    Takaya M; Ishii K; Kubota I; Shirakawa O
    Psychogeriatrics; 2019 Jul; 19(4):399-401. PubMed ID: 30712283
    [No Abstract]   [Full Text] [Related]  

  • 45. Brain PET Imaging: Frontotemporal Dementia.
    Ward J; Ly M; Raji CA
    PET Clin; 2023 Jan; 18(1):123-133. PubMed ID: 36442960
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Accuracy of Biomarker Testing for Neuropathologically Defined Alzheimer Disease in Older Adults With Dementia.
    Fink HA; Linskens EJ; Silverman PC; McCarten JR; Hemmy LS; Ouellette JM; Greer NL; Wilt TJ; Butler M
    Ann Intern Med; 2020 May; 172(10):669-677. PubMed ID: 32340038
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET.
    Fällmar D; Haller S; Lilja J; Danfors T; Kilander L; Tolboom N; Egger K; Kellner E; Croon PM; Verfaillie SCJ; van Berckel BNM; Ossenkoppele R; Barkhof F; Larsson EM
    Eur Radiol; 2017 Oct; 27(10):4237-4246. PubMed ID: 28374078
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Molecular imaging of dementia.
    Mori T; Maeda J; Shimada H; Higuchi M; Shinotoh H; Ueno S; Suhara T
    Psychogeriatrics; 2012 Jun; 12(2):106-14. PubMed ID: 22712644
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical heterogeneity of frontotemporal dementia and Parkinsonism linked to chromosome 17 caused by MAPT N279K mutation in relation to tau positron emission tomography features.
    Ikeda A; Shimada H; Nishioka K; Takanashi M; Hayashida A; Li Y; Yoshino H; Funayama M; Ueno Y; Hatano T; Sahara N; Suhara T; Higuchi M; Hattori N
    Mov Disord; 2019 Apr; 34(4):568-574. PubMed ID: 30773680
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Recommendations for the use of PET imaging biomarkers in the diagnosis of neurodegenerative conditions associated with dementia: SEMNIM and SEN consensus.
    Arbizu J; García-Ribas G; Carrió I; Garrastachu P; Martínez-Lage P; Molinuevo JL
    Rev Esp Med Nucl Imagen Mol; 2015; 34(5):303-13. PubMed ID: 26099942
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Distinct patterns of amyloid-dependent tau accumulation in Lewy body diseases.
    Lee SH; Cho H; Choi JY; Lee JH; Ryu YH; Lee MS; Lyoo CH
    Mov Disord; 2018 Feb; 33(2):262-272. PubMed ID: 29168583
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Alzheimer's Dementia: The Emerging Role of Positron Emission Tomography.
    Tripathi SM; Murray AD
    Neuroscientist; 2022 Oct; 28(5):507-519. PubMed ID: 33660556
    [TBL] [Abstract][Full Text] [Related]  

  • 53. FTD spectrum: Neuroimaging across the FTD spectrum.
    Whitwell JL
    Prog Mol Biol Transl Sci; 2019; 165():187-223. PubMed ID: 31481163
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Role of semiquantitative assessment of regional binding potential in 123I-FP-CIT SPECT for the differentiation of frontotemporal dementia, dementia with Lewy bodies, and Alzheimer's dementia.
    Spehl TS; Frings L; Hellwig S; Weiller C; Hüll M; Meyer PT; Amtage F
    Clin Nucl Med; 2015 Jan; 40(1):e27-33. PubMed ID: 25140560
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Feasibility and acceptance of simultaneous amyloid PET/MRI.
    Schütz L; Lobsien D; Fritzsch D; Tiepolt S; Werner P; Schroeter ML; Berrouschot J; Saur D; Hesse S; Jochimsen T; Rullmann M; Sattler B; Patt M; Gertz HJ; Villringer A; Claßen J; Hoffmann KT; Sabri O; Barthel H
    Eur J Nucl Med Mol Imaging; 2016 Nov; 43(12):2236-2243. PubMed ID: 27435367
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Clinical utility of 18F-FDG-PET/MRI brain in dementia: Preliminary experience from a geriatric clinic in South India.
    Mukku SSR; Sivakumar PT; Nagaraj C; Mangalore S; Harbishettar V; Varghese M
    Asian J Psychiatr; 2019 Aug; 44():99-105. PubMed ID: 31336358
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Update on PET in neurodegenerative and neuroinflammatory disorders manifesting on a behavioural level: imaging for differential diagnosis.
    Hellwig S; Domschke K; Meyer PT
    Curr Opin Neurol; 2019 Aug; 32(4):548-556. PubMed ID: 31107281
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Imaging of neurodegenerative cognitive and behavioral disorders: practical considerations for dementia clinical practice.
    Atri A
    Handb Clin Neurol; 2016; 136():971-84. PubMed ID: 27430453
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Three presenile patients in which neuropsychological and neuroimaging examinations suggest possible progression to dementia with Lewy bodies.
    Ota K; Iseki E; Murayama N; Chiba Y; Fujishiro H; Kasanuki K; Manabe Y; Arai H; Sato K
    Psychogeriatrics; 2014 Mar; 14(1):72-80. PubMed ID: 24528622
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Imaging correlations of tau, amyloid, metabolism, and atrophy in typical and atypical Alzheimer's disease.
    Whitwell JL; Graff-Radford J; Tosakulwong N; Weigand SD; Machulda MM; Senjem ML; Spychalla AJ; Vemuri P; Jones DT; Drubach DA; Knopman DS; Boeve BF; Ertekin-Taner N; Petersen RC; Lowe VJ; Jack CR; Josephs KA
    Alzheimers Dement; 2018 Aug; 14(8):1005-1014. PubMed ID: 29605222
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.